Many herbs have been shown to safely and successfully treat hyperlipidemia. However, the molecular mechanisms underlying their treatment remain unclear. In this study, 103 prescriptions for the treatment of hyperlipidemia containing 146 herbs were screened. Cluster analyses identified a core prescription comprising five herbs, namely, Crataegus pinnatifida (Shan Zha), Cassiae semen (Jue Ming Zi), Alisma orientale (Sam.) Juz. (Ze Xie), Salvia miltiorrhiza (Dan Shen), and RadixPolygoni Multiflori (He Shou Wu), in combination for the treatment of hyperlipidemia. Next, 9, 62, 5, 132, and 34 potential targets for each of the core herbs and a total of 512 hyperlipidemia-related protein targets were detected. Finally, 40 targets shared by core herbs and hyperlipidemia were identified. IL6, AKT1, IL1B, PTGS2, VEGFA, PPARG, and NOS3 were the seven proteins that were found to be most important in the treatment of hyperlipidemia. Interestingly, the Kyoto Encyclopedia of Genes and Genomes pathway indicated that these targets were mainly enriched in the lipid and atherosclerosis pathway and the cancer pathway. In addition, core target proteins such as AKT1, PTGS2, and PPARG have been demonstrated to play critical roles in hyperlipidemia and pancreatic cancer. Significant affinity between bioactive chemicals and proteins involved in cancer pathways was found by molecular docking. Molecular docking results showed that AKT1, PTGS2, and PPARG exhibited good binding ability with three bioactive chemicals, including 3-beta-hydroxymethyllenetanshiquinone, danshexinkum d, and physciondiglucoside. The treatment of hyperlipidemia by herbs may be mediated through the modulation of proteins associated with the cancer pathway. This study helps to provide a theoretical basis for future combined therapy for hyperlipidemia and cancer.
Get full access to this article
View all access options for this article.
References
1.
SunG, LiX, WeiJ, et al.Pharmacodynamic substances in Salvia miltiorrhiza for prevention and treatment of hyperlipidemia and coronary heart disease based on lipidomics technology and network pharmacology analysis. Biomed Pharmacother, 2021; 141:111846.
2.
PanL, YangZ, WuY, et al.The prevalence, awareness, treatment and control of dyslipidemia among adults in China. Atherosclerosis, 2016; 248:2–9; doi: 10.1016/j.atherosclerosis.2016.02.006
3.
YanJ, KangJ, ChenB, et al.Effects of Cichorium glandulosum on hyperglycemia, dyslipidemia and intestinal flora in db/db mice. J Funct Foods, 2022; 97:105240.
4.
YangL, LiZ, SongY, et al.Study on urine metabolic profiling and pathogenesis of hyperlipidemia. Clin Chim Acta, 2019; 495:365–373; doi: 10.1016/j.cca.2019.05.001
5.
KopinL, LowensteinC. Dyslipidemia. Ann Intern Med, 2017; 167(11):Itc81–Itc96; doi: 10.7326/aitc201712050
6.
KarrS. Epidemiology and management of hyperlipidemia. Am J Manag Care, 2017; 23(Suppl 9):S139–S148.
AliMR, RezaAA, HaqueMA, et al.Exploring the therapeutic potential of edible vegetables, fruits, and spices against cancer in various cell lines. J Cancer, 2024; 15(3):577–589.
9.
MostofaMG, RezaAA, KhanZ, et al.Apoptosis-inducing anti-proliferative and quantitative phytochemical profiling with in silico study of antioxidant-rich Leea aequata L. leaves. Heliyon, 2024; 10(1):e23400.
10.
ŞahinTÖ, YılmazB, YeşilyurtN, et al.Recent insights into the nutritional immunomodulation of cancer‐related microRNAs. Phytother Res, 2023; 37(10):4375–4397.
11.
D’AvinoD, CerquaI, UllahH, et al.Beneficial effects of Astragalus membranaceus (Fisch.) bunge extract in controlling inflammatory response and preventing asthma features. Int J Mol Sci, 2023; 24(13):10954.
12.
KhanMF, KaderFB, ArmanM, et al.Pharmacological insights and prediction of lead bioactive isolates of dita bark through experimental and computer-aided mechanism. Biomed Pharmacother, 2020; 131:110774.
13.
AçarY, AğagündüzD, De CiccoP, et al.Flavonoids: Their putative neurologic roles, epigenetic changes, and gut microbiota alterations in Parkinson’s disease. Biomed Pharmacother, 2023; 168:115788.
14.
FernandezJ, SilvánB, Entrialgo-CadiernoR, et al.Antiproliferative and palliative activity of flavonoids in colorectal cancer. Biomed Pharmacother, 2021; 143:112241.
15.
DaiR, SunY, SuR, et al.Anti-Alzheimer’s disease potential of traditional Chinese medicinal herbs as inhibitors of BACE1 and AChE enzymes. Biomed Pharmacother, 2022; 154:113576.
16.
ElkordyAA, Haj-AhmadRR, AwaadAS, et al.An overview on natural product drug formulations from conventional medicines to nanomedicines: Past, present and future. J Drug Deliv Sci Technol, 2021; 63:102459.
17.
ZhouW, ChenZ, LiW, et al.Systems pharmacology uncovers the mechanisms of anti-asthma herbal medicine intervention (ASHMI) for the prevention of asthma. J Funcy Foods, 2019; 52:611–619.
18.
ZhangM, LiX, LiangH, et al.Semen Cassiae extract improves glucose metabolism by promoting GLUT4 translocation in the skeletal muscle of diabetic rats. Front Pharmacol, 2018; 9:235.
19.
GuoM, LiuY, GaoZ-Y, et al.Chinese herbal medicine on dyslipidemia: Progress and perspective. Evid Based Complementary Altern Med, 2014; 2014:1–11.
20.
RaufA, AkramM, AnwarH, et al.Therapeutic potential of herbal medicine for the management of hyperlipidemia: Latest updates. Environ Sci Pollut Res, 2022; 29(27):40281–40301.
21.
ZhangX, GaoR, ZhouZ, et al.Uncovering the mechanism of Huanglian-Wuzhuyu herb pair in treating nonalcoholic steatohepatitis based on network pharmacology and experimental validation. J Ethnopharmacol, 2022; 296:115405.
22.
ZhangG-B, LiQ-y, ChenQ-L, et al.Network pharmacology: A new approach for Chinese herbal medicine research. Evid Based Complementary Altern Med, 2013; 2013:1–9.
23.
LiuH, LiX, XieJ, et al.Gypenoside L and Gypenoside LI inhibit proliferation in renal cell carcinoma via regulation of the MAPK and arachidonic acid metabolism pathways. Front Pharmacol, 2022; 13:820639; doi: 10.3389/fphar.2022.820639
24.
YangYH, YangJ, JiangQH. Hypolipidemic effect of gypenosides in experimentally induced hypercholesterolemic rats. Lipids Health Dis, 2013; 12:154; doi: 10.1186/1476-511x-12-154
25.
ZhengK, LiaoC, LiY, et al.Gypenoside L, isolated from Gynostemma pentaphyllum, induces cytoplasmic vacuolation death in hepatocellular carcinoma cells through reactive-oxygen-species-mediated unfolded protein response. J Agric Food Chem, 2016; 64(8):1702–1711; doi: 10.1021/acs.jafc.5b05668
26.
XingSF, LiuLH, ZuML, et al.The inhibitory effect of gypenoside stereoisomers, gypenoside L and gypenoside LI, isolated from Gynostemma pentaphyllum on the growth of human lung cancer A549 cells. J Ethnopharmacol, 2018; 219:161–172; doi: 10.1016/j.jep.2018.03.012
27.
MaJ, HuX, LiaoC, et al.Gypenoside L inhibits proliferation of liver and esophageal cancer cells by inducing senescence. Molecules, 2019; 24(6); doi: 10.3390/molecules24061054
28.
ZuML, PiaoXL, GaoJM, et al.Monomer gypenoside LI from Gynostemma pentaphyllum inhibits cell proliferation and upregulates expression of miR-128-3p in melanoma cells. J Biochem Mol Toxicol, 2020; 34(5):e22460; doi: 10.1002/jbt.22460
29.
ZuML, DuanY, XieJB, et al.Gypenoside LI arrests the cell cycle of breast cancer in G0/G1 phase by down-regulating E2F1. J Ethnopharmacol, 2021; 273:114017; doi: 10.1016/j.jep.2021.114017
30.
LiJ, LiuH, YangZ, et al.Synergistic effects of cryptotanshinone and senkyunolide I in guanxinning tablet against endogenous thrombus formation in zebrafish. Front Pharmacol, 2020; 11:622787.
31.
ZhouX, SetoSW, ChangD, et al.Synergistic effects of Chinese herbal medicine: A comprehensive review of methodology and current research. Front Pharmacol, 2016; 7:201.
32.
LeenaMM, SilviaMG, VinithaK, et al.Synergistic potential of nutraceuticals: Mechanisms and prospects for futuristic medicine. Food Funct, 2020; 11(11):9317–9337.
33.
TangZ, KangB, LiC, et al.GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res, 2019; 47(W1):W556–W560.
34.
DehghaniS, MehriS, HosseinzadehH. The effects of Crataegus pinnatifida (Chinese hawthorn) on metabolic syndrome: A review. Iran J Basic Med Sci, 2019; 22(5):460–468.
35.
YangJ, ZhuA, XiaoS, et al.Anthraquinones in the aqueous extract of Cassiae semen cause liver injury in rats through lipid metabolism disorder. Phytomedicine, 2019; 64:153059; doi: 10.1016/j.phymed.2019.153059
36.
LiaoM, ShangH, LiY, et al.An integrated approach to uncover quality marker underlying the effects of Alisma orientale on lipid metabolism, using chemical analysis and network pharmacology. Phytomedicine, 2018; 45:93–104.
37.
FanH, LiM, YuL, et al.Effects of Danhong Injection on platelet aggregation in hyperlipidemia rats. J Ethnopharmacol, 2018; 212:67–73; doi: 10.1016/j.jep.2017.10.017
38.
WanH, TianY, JiangH, et al.A NMR-based drug screening strategy for discovering active substances from herbal medicines: Using Radix Polygoni Multiflori as example. J Ethnopharmacol, 2020; 254:112712.
39.
LuoL, JiangJ, WangC, et al.Analysis on herbal medicines utilized for treatment of COVID-19. Acta Pharm Sin B, 2020; 10(7):1192–1204; doi: 10.1016/j.apsb.2020.05.007
40.
LeeDYW, LiQY, LiuJ, et al.Traditional Chinese herbal medicine at the forefront battle against COVID-19: Clinical experience and scientific basis. Phytomedicine, 2021; 80:153337; doi: 10.1016/j.phymed.2020.153337
41.
FuB, WangN, TanH-Y, et al.Multi-component herbal products in the prevention and treatment of chemotherapy-associated toxicity and side effects: A review on experimental and clinical evidences. Front Pharmacol, 2018; 9:1394.
42.
NordestgaardBG, VarboA. Triglycerides and cardiovascular disease. Lancet, 2014; 384(9943):626–635.
43.
RosamondW, FlegalK, FurieK, et al.Heart disease and stroke statistics—2008 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 2008; 117(4):e25–e146.
44.
SentinelliF, FilippiE, FallarinoM, et al.The 3′-UTR C>T polymorphism of the oxidized LDL-receptor 1 (OLR1) gene does not associate with coronary artery disease in Italian CAD patients or with the severity of coronary disease. Nutr Metab Cardiovasc Dis, 2006; 16(5):345–352; doi: 10.1016/j.numecd.2005.06.002
45.
DashnamoorthyR, AbermilN, BehestiA, et al.The lipid addiction of Diffuse Large B-Cell Lymphoma (DLBCL) and potential treatment strategies with novel Fatty Acid Synthase (FASN) small molecule inhibitors. Blood, 2014; 124(21):4490–4490; doi: 10.1182/blood.V124.21.4490.4490
46.
LiY, YangW, ZhengY, et al.Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis. J Exp Clin Cancer Res, 2023; 42(1):6.
47.
Van DuijnhovenFJ, Bueno-De-MesquitaHB, CalligaroM, et al.Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European prospective investigation into cancer and nutrition. Gut, 2011; 60(8):1094–1102.
48.
KwaifaIK, BahariH, YongYK, et al.Endothelial dysfunction in obesity-induced inflammation: Molecular mechanisms and clinical implications. Biomolecules, 2020; 10(2):291.
49.
CarptenJD, FaberAL, HornC, et al.A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature, 2007; 448(7152):439–444.
50.
AlwhaibiA, VermaA, AdilMS, et al.The unconventional role of Akt1 in the advanced cancers and in diabetes-promoted carcinogenesis. Pharmacol Res, 2019; 145:104270.
51.
MalikSN, BrattainM, GhoshPM, et al.Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res, 2002; 8(4):1168–1171.
WangHQ, AltomareDA, SkeleKL, et al.Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene, 2005; 24(22):3574–3582; doi: 10.1038/sj.onc.1208463
54.
LinX-M, LiS, ZhouC, et al.Cisplatin induces chemoresistance through the PTGS2-mediated anti-apoptosis in gastric cancer. Int J Biochem Cell Biol, 2019; 116:105610.
55.
BellCR, PellyVS, MoeiniA, et al.Chemotherapy-induced COX-2 upregulation by cancer cells defines their inflammatory properties and limits the efficacy of chemoimmunotherapy combinations. Nat Commun, 2022; 13(1):2063; doi: 10.1038/s41467-022-29606-9
56.
PuD, YinL, HuangL, et al.Cyclooxygenase-2 inhibitor: A potential combination strategy with immunotherapy in cancer. Front Oncol, 2021; 11:637504; doi: 10.3389/fonc.2021.637504
57.
WangB, WuL, ChenJ, et al.Metabolism pathways of arachidonic acids: Mechanisms and potential therapeutic targets. Signal Transduct Target Ther, 2021; 6(1):94; doi: 10.1038/s41392-020-00443-w
58.
WangC, ZhangX, LuoL, et al.COX-2 Deficiency promotes white adipogenesis via PGE2-mediated paracrine mechanism and exacerbates diet-induced obesity. Cells, 2022; 11(11); doi: 10.3390/cells11111819
59.
WilsonHE, StantonDA, RellickS, et al.Breast cancer-associated skeletal muscle mitochondrial dysfunction and lipid accumulation is reversed by PPARG. Am J Physiol Cell Physiol, 2021; 320(4):C577–C590.
60.
XiongW, ZhaoX, VillacortaL, et al.Brown adipocyte-specific PPARγ (peroxisome proliferator-activated receptor γ) deletion impairs perivascular adipose tissue development and enhances atherosclerosis in mice. Arterioscler Thromb Vasc Biol, 2018; 38(8):1738–1747.
61.
MontaigneD, ButruilleL, StaelsB. PPAR control of metabolism and cardiovascular functions. Nat Rev Cardiol, 2021; 18(12):809–823.
62.
ZhangZ, LiuJ, LiuY, et al.Virtual screening of the multi-gene regulatory molecular mechanism of Si-Wu-tang against non-triple-negative breast cancer based on network pharmacology combined with experimental validation. J Ethnopharmacol, 2021; 269:113696; doi: 10.1016/j.jep.2020.113696
63.
NelsonER, WardellSE, JasperJS, et al.27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science, 2013; 342(6162):1094–1098.
64.
HisM, ZelekL, DeschasauxM, et al.Prospective associations between serum biomarkers of lipid metabolism and overall, breast and prostate cancer risk. Eur J Epidemiol, 2014; 29(2):119–132.
65.
ZhuY, AupperleeMD, ZhaoY, et al.Pubertal and adult windows of susceptibility to a high animal fat diet in Trp53-null mammary tumorigenesis. Oncotarget, 2016; 7(50):83409–83423.
66.
RazaS, MeyerM, GoodyearC, et al.The cholesterol metabolite 27-hydroxycholesterol stimulates cell proliferation via ERβ in prostate cancer cells. Cancer Cell Int, 2017; 17:52–11.
67.
MorelS, LeahyJ, FournierM, et al.Lipid and lipoprotein abnormalities in acute lymphoblastic leukemia survivors [S]. J Lipid Res, 2017; 58(5):982–993.
68.
ZhouT, ZhanJ, FangW, et al.Serum low-density lipoprotein and low-density lipoprotein expression level at diagnosis are favorable prognostic factors in patients with small-cell lung cancer (SCLC). BMC Cancer, 2017; 17(1):269.
69.
ByonCH, HardyRW, RenC, et al.Free fatty acids enhance breast cancer cell migration through plasminogen activator inhibitor-1 and SMAD4. Lab Invest, 2009; 89(11):1221–1228.
70.
NielsenSF, NordestgaardBG, BojesenSE. Statin use and reduced cancer-related mortality. N Engl J Med, 2012; 367(19):1792–1802.
71.
GuptaA, StokesW, EguchiM, et al.Statin use associated with improved overall and cancer specific survival in patients with head and neck cancer. Oral Oncol, 2019; 90:54–66; doi: 10.1016/j.oraloncology.2019.01.019
72.
YelekC, MignionL, PaquotA, et al.Tumor metabolism is affected by obesity in preclinical models of triple-negative breast cancer. Cancers (Basel), 2022; 14(3); doi: 10.3390/cancers14030562
73.
FuY, ZouT, ShenX, et al.Lipid metabolism in cancer progression and therapeutic strategies. MedComm (2020), 2021; 2(1):27–59; doi: 10.1002/mco2.27
74.
TerryAR, HayN. Emerging targets in lipid metabolism for cancer therapy. Trends Pharmacol Sci, 2024; 45(6):537–551; doi: 10.1016/j.tips.2024.04.007
75.
WuH, WuX, ZhaoM, et al.Regulating cholesterol in tumorigenesis: A novel paradigm for tumor nanotherapeutics. Int J Nanomedicine, 2024; 19:1055–1076; doi: 10.2147/IJN.S439828
76.
SharmaB, ChughLK. Two isoforms of lipoxygenase from mature grains of pearl millet [Pennisetum glaucum (L.) R. Br.]: purification and physico-chemico-kinetic characterization. J Food Sci Technol, 2017; 54(6):1577–1584; doi: 10.1007/s13197-017-2589-5
77.
SimopoulouT, MalizosKN, TsezouA. Lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) expression in human articular chondrocytes. Clin Exp Rheumatol, 2007; 25(4):605–612.
78.
YaoX, JiangW, YuD, et al.Luteolin inhibits proliferation and induces apoptosis of human melanoma cells in vivo and in vitro by suppressing MMP-2 and MMP-9 through the PI3K/AKT pathway. Food Funct, 2019; 10(2):703–712; doi: 10.1039/c8fo02013b
79.
WuC, ZhaoW, ZhangX, et al.Neocryptotanshinone inhibits lipopolysaccharide-induced inflammation in RAW264.7 macrophages by suppression of NF-κB and iNOS signaling pathways. Acta Pharm Sin B, 2015; 5(4):323; doi: 10.1016/j.apsb.2015.01.010
80.
DuM, ShenP, TanR, et al.Aloe-emodin inhibits the proliferation, migration, and invasion of melanoma cells via inactivation of the Wnt/beta-catenin signaling pathway. Ann Transl Med, 2021; 9(23):1722; doi: 10.2103/7/atm-21-5437
81.
JiangD, DingS, MaoZ, et al.Integrated analysis of potential pathways by which aloe-emodin induces the apoptosis of colon cancer cells. Cancer Cell Int, 2021; 21(1):238; doi: 10.1186/s12935-021-01942-8
82.
ZhangH, YanH, ZhouX, et al.The protective effects of resveratrol against radiation-induced intestinal injury. BMC Complement Altern Med, 2017; 17(1):410; doi: 10.1186/s12906-017-1915-9
LiuL, YangX, LiaoY, et al.Resveratrol alleviates Ang II-induced vascular smooth muscle cell senescence by upregulating E2F1/SOD2 axis. Toxicol Res (Camb), 2022; 11(5):831–840; doi: 10.1093/toxres/tfac051
85.
CaesarLK, CechNB. Synergy and antagonism in natural product extracts: When 1 + 1 does not equal 2. Nat Prod Rep, 2019; 36(6):869–888; doi: 10.1039/c9np00011a
86.
ChughR, SangwanV, PatilSP, et al.A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Sci Transl Med, 2012; 4(156):156ra139.
87.
HaqA, PhillipsA, MiedemaMD. Acute severe hyperlipidemia leading to a diagnosis of pancreatic cancer in an elderly woman. AIM Clinical Cases, 2022; 1(6):e220119.
88.
TakahashiM, HoriM, MutohM, et al.Experimental animal models of pancreatic carcinogenesis for prevention studies and their relevance to human disease. Cancers (Basel), 2011; 3(1):582–602.
89.
KolodecikT, ShugrueC, AshatM, et al.Risk factors for pancreatic cancer: Underlying mechanisms and potential targets. Front Physiol, 2013; 4:415.
90.
TakahashiM, MutohM, IshigamoriR, et al.Involvement of Inflammatory Factors in Pancreatic Carcinogenesis and Preventive Effects of Anti-Inflammatory Agents. Springer; 2013.
91.
WangM, XuJ, ZhangY, et al.Integrated multiplatform-based metabonomics and network analysis to explore the mechanism of Polygonum cuspidatum on hyperlipidemia. J Chromatogr B Analyt Technol Biomed Life Sci, 2021; 1176:122769.
92.
EnogieruAB, HaylettW, HissDC, et al.Rutin as a potent antioxidant: Implications for neurodegenerative disorders. Oxid Med Cell Longev, 2018; 2018:6241017; doi: 10.1155/2018/6241017
93.
FarhaAK, GanRY, LiHB, et al.The anticancer potential of the dietary polyphenol rutin: Current status, challenges, and perspectives. Crit Rev Food Sci Nutr, 2022; 62(3):832–859; doi: 10.1080/10408398.2020.1829541
94.
ImaniA, MalekiN, BohlouliS, et al.Molecular mechanisms of anticancer effect of rutin. Phytother Res, 2021; 35(5):2500–2513; doi: 10.1002/ptr.6977
95.
LiuY, SunZ, DongR, et al.Rutin ameliorated lipid metabolism dysfunction of diabetic NAFLD via AMPK/SREBP1 pathway. Phytomedicine, 2024; 126:155437; doi: 10.1016/j.phymed.2024.155437
96.
WuCH, LinMC, WangHC, et al.Rutin inhibits oleic acid induced lipid accumulation via reducing lipogenesis and oxidative stress in hepatocarcinoma cells. J Food Sci, 2011; 76(2):T65–T72; doi: 10.1111/j.1750-3841.2010.02033.x
97.
WangZ-Y, JiangZ-M, XiaoP-T, et al.The mechanisms of baicalin ameliorate obesity and hyperlipidemia through a network pharmacology approach. Eur J Pharmacol, 2020; 878:173103; doi: 10.1016/j.ejphar.2020.173103
98.
SinghS, MeenaA, LuqmanS. Baicalin mediated regulation of key signaling pathways in cancer. Pharmacol Res, 2021; 164:105387.
99.
PangH, WuT, PengZ, et al.Baicalin induces apoptosis and autophagy in human osteosarcoma cells by increasing ROS to inhibit PI3K/Akt/mTOR, ERK1/2 and β-catenin signaling pathways. J Bone Oncol, 2022; 33:100415.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
